O steoarthritis (OA) is a highly prevalent, disabling, and costly condition that has been recognized by the United States Food and Drug Administration as a serious disease with unmet medical need (1-3). OA is understood as a disease of the whole joint, involving structural damage of the articular cartilage, subchondral bone, ligaments, capsule, synovial membrane, and periarticular muscles (4,5). Pain is the predominant symptom and is a major driving force in clinical decision making and health service attention (6). Current management of OA is primarily focused on symptom control. Intra-articular corticosteroid (IACS) injections are often used for pain management of hip and knee OA in patients who have not responded to oral or topical analgesics and are frequently intended to delay total joint replacement surgery if patients are young or hesitant to undergo surgery right away (7). A recent case series presented data on possible negative outcomes of IACS injection as perceived from a radiologic perspective (8). These findings included accelerated OA progression, subchondral insufficiency fracture, complications of pre-existing osteonecrosis, and rapid joint destruction including bone loss. Another recent uncontrolled retrospective observational study that focused on IACS injection of the hip and subsequent joint events reported that almost half of the patients treated with IACS injections exhibited signs of radiographic progression